Comparable Long-Term Efficacy of Lopinavir/Ritonavir and Similar Drug-Resistance Profiles in Different HIV-1 Subtypes |
| |
| Authors: | Zehava Grossman Jonathan M. Schapiro Itzchak Levy Daniel Elbirt Michal Chowers Klaris Riesenberg Karen Olstein-Pops Eduardo Shahar Valery Istomin Ilan Asher Bat-Sheva Gottessman Yonat Shemer Hila Elinav Gamal Hassoun Shira Rosenberg Diana Averbuch Keren Machleb-Guri Zipi Kra-Oz Sara Radian-Sade Hagit Rudich Daniela Ram Shlomo Maayan Nancy Agmon-Levin Zev Sthoeger |
| |
| Affiliation: | 1. Public Health School, Tel-Aviv University, Tel-Aviv, Israel.; 2. Sheba Medical Center, Ramat Gan, Israel.; 3. Kaplan Medical Center, Rehovot, Israel.; 4. Meir Medical Center, Kfar Saba, Israel.; 5. Soroka Medical Center, Beer Sheva, Israel.; 6. Hadassah Medical Center, Jerusalem, Israel.; 7. Rambam Medical Center, Haifa, Israel.; 8. Hillel Yaffe Medical Center, Hadera, Israel.; 9. National HIV Reference Lab, PHL, MOH, Ramat Gan, Israel.; University of Pittsburgh, United States of America, |
| |
| Abstract: | BackgroundAnalysis of potentially different impact of Lopinavir/Ritonavir (LPV/r) on non-B subtypes is confounded by dissimilarities in the conditions existing in different countries. We retrospectively compared its impact on populations infected with subtypes B and C in Israel, where patients infected with different subtypes receive the same treatment.MethodsClinical and demographic data were reported by physicians. Resistance was tested after treatment failure. Statistical analyses were conducted using SPSS.Results607 LPV/r treated patients (365 male) were included. 139 had HIV subtype B, 391 C, and 77 other subtypes. At study end 429 (71%) were receiving LPV/r. No significant differences in PI treatment history and in median viral-load (VL) at treatment initiation and termination existed between subtypes. MSM discontinued LPV/r more often than others even when the virologic outcome was good (p = 0.001). VL was below detection level in 81% of patients for whom LPV/r was first PI and in 67% when it was second (P = 0.001). Median VL decrease from baseline was 1.9±0.1 logs and was not significantly associated with subtype. Median CD4 increase was: 162 and 92cells/µl, respectively, for patients receiving LPV/r as first and second PI (P = 0.001), and 175 and 98, respectively, for subtypes B and C (P<0.001). Only 52 (22%) of 237 patients genotyped while under LPV/r were fully resistant to the drug; 12(5%) were partially resistant. In48%, population sequencing did not reveal resistance to any drug notwithstanding the virologic failure. No difference was found in the rates of resistance development between B and C (p = 0.16).ConclusionsTreatment with LPV/r appeared efficient and tolerable in both subtypes, B and C, but CD4 recovery was significantly better in virologically suppressed subtype-B patients. In both subtypes, LPV/r was more beneficial when given as first PI. Mostly, reasons other than resistance development caused discontinuation of treatment. |
| |
| Keywords: | |
|
|
